Page last updated: 2024-12-08

5-hydroxyferulic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

5-hydroxyferulic acid : Ferulic acid in which the ring hydrogen at position 5 is substituted by a hydroxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

(E)-5-hydroxyferulic acid : The E-isomer of 5-hydroxyferulic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID446834
CHEMBL ID4205174
CHEBI ID20582
CHEBI ID2069
SCHEMBL ID10085810
MeSH IDM0194772

Synonyms (40)

Synonym
3-(3,4-dihydroxy-5-methoxyphenyl)prop-2-enoic acid
1782-55-4
3,4-dihydroxy-5-methoxycinnamic acid ,
3-(3,4-dihydroxy-5-methoxyphenyl)acrylic acid
CHEBI:20582
3-methoxycaffeic acid
3-(3,4-dihydroxy-5-methoxyphenyl)-2-propenoic acid
HFL ,
C05619
5-hydroxyferulic acid methyl ester
2041-35-2
5-hydroxyferulic acid
(e)-3-(3,4-dihydroxy-5-methoxyphenyl)prop-2-enoic acid
2-propenoic acid, 3-(3,4-dihydroxy-5-methoxyphenyl)-
2-propenoic acid, 3-(3,4-dihydroxy-5-methoxyphenyl)-, (2e)-
110642-42-7
(e)-3-(3,4-dihydroxy-5-methoxy-phenyl)prop-2-enoic acid
CHEBI:2069
3-methoxy-4,5-dihydroxy-trans-cinnamic acid
(2e)-3-(3,4-dihydroxy-5-methoxyphenyl)prop-2-enoic acid
trans-5-hydroxyferulic acid
(e)-5-hydroxyferulic acid
(2e)-3-(3,4-dihydroxy-5-methoxyphenyl)-2-propenoic acid
SCHEMBL10085810
hydroxyferulic acid
3,4-dihydroxy-5-methoxycinnamic acid, >=95.0% (hplc)
mfcd03002791
3-(3,4-dihydroxy-5-methoxy)-2-propenoic acid, 9ci
3,4-dihydroxy-5-methoxycinnamoic acid
hydroxy ferulic acid
HY-133068
Q1033729
CS-0110087
CHEMBL4205174
cinnamic acid, 3,4-dihydroxy-5-methoxy-
r3lzy3e4he ,
PD164672
DTXSID001347297
EN300-1828675
AKOS040736324
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
5-hydroxyferulic acidFerulic acid in which the ring hydrogen at position 5 is substituted by a hydroxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
free phenylpropanoid acid biosynthesis410

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1378049Antiglycation activity in bovine serum albumin assessed as inhibition of advanced glycated end product formation in presence of D-glucose by spectrofluorimetric analysis2017Journal of natural products, 07-28, Volume: 80, Issue:7
Phylogenomics of 2,4-Diacetylphloroglucinol-Producing Pseudomonas and Novel Antiglycation Endophytes from Piper auritum.
AID1378056Antiglycation activity in bovine serum albumin assessed as inhibition of advanced glycated end product formation in presence of D-glucose and ferulic acid by spectrofluorimetric analysis2017Journal of natural products, 07-28, Volume: 80, Issue:7
Phylogenomics of 2,4-Diacetylphloroglucinol-Producing Pseudomonas and Novel Antiglycation Endophytes from Piper auritum.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (21.05)18.2507
2000's8 (42.11)29.6817
2010's7 (36.84)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.26%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (94.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]